Newscast – Page 123 – media

NHS Confed orders reports into NHS funding needs

The NHS Confederation has tasked the Institute for Fiscal Studies and the Health Foundation with analysing the funding needs of the UK’s health and care systems over the next 15 years.
- Source: pharmatimes
- 508
- January 12, 2018
health NHS polices
Depression medication initiation may lower oral antidiabetic drug adherence in diabetes

Adults with type 2 diabetes and major depressive disorders who begin using second-generation antipsychotics are more likely to have at least a 10% decline in oral antidiabetic drug use 180 to 365 days after initiation compared with nonusers of second-generation antipsychotics, according to a study.
- Source: Healio
- 633
- January 12, 2018
antipsychotics diabetes Researches
Sex hormone-binding globulin associated with androgen deficiency

Higher levels of sex hormone-binding globulin were associated with androgen deficiency in men, independent of total testosterone level, researchers in Italy reported.
- Source: healio
- 423
- January 12, 2018
androgen deficiency Researches sex hormone
Celgene to Acquire Impact Biomedicines, Adding Fedratinib to Its Pipeline of Novel Therapies for Hematologic Malignancies

Celgene Corporation (CELG) and Impact Biomedicines today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera. Under the terms of the agreement, Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for myelofibrosis. Additional future payments for regulatory approvals in additional indications and sales-based milestones are also possible.
- Source: finance.yahoo
- 510
- January 12, 2018
Celgene FDA Fedratinib Impact Market Views myelofibrosis
GE Healthcare and Roche join forces to create clinical decision support tools

GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
- Source: MedCityNews
- 577
- January 12, 2018
Clinical Company Insight Roche
New AI technology significantly improves human kidney analysis

The ability to quantify the extent of kidney damage and predict the life remaining in the kidney, using an image obtained at the time when a patient visits the hospital for a kidney biopsy, now is possible using a computer model based on artificial intelligence (AI).
- Source: Medical Xpress
- 637
- January 12, 2018
AI kidney Researches
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**

Novartis announced the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS). SURPASS is the first head-to-head clinical trial in AS investigating superiority of Cosentyx in slowing spinal bone damage versus proposed biosimilar adalimumab**. SURPASS is currently recruiting patients, with the 'first patient first visit' already achieved in November 2017.
- Source: drugdu
- 724
- January 11, 2018
adalimumab** Company Insight Cosentyx® Novartis Researches
Women who work nights face higher cancer risk

Women who regularly work the night shift in Europe and North America may face a 19 percent higher risk of cancer than those who work during the day, said a study Monday.
- Source: msn
- 582
- January 11, 2018
breast cancer cancer Researches
Fitbit has invested $6 million in glucose-monitoring startup Sano

Fitbit has invested $6 million in a glucose-monitoring startup called Sano, in what appears to be part of Fitbit’s larger plans to make its fitness devices more valuable for overall health.
- Source: The Verge
- 403
- January 11, 2018
Company Insight Glucose Monitoring System wearables
Microsoft Wants to Use Artificial Intelligence to Make CRISPR More Accurate

he gene-editing technology CRISPR could very well one day rid the world of its most devastating diseases, allowing us to simply edit away the genetic code responsible for an illness. One of the things standing in the way of turning that fantasy into reality, though, is the problem of off-target effects. Now Microsoft is hoping to use artificial intelligence to fix this problem.
- Source: GIZMODO
- 419
- January 11, 2018
AI CRISPR Microsoft Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.